DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20184125

Comparative study of various oxytocics in management of third stage of labour

Shrinivas N. Gadappa, Deepika Sharma, Yogita Gavit

Abstract


Background: Causes of maternal mortality are haemorrhages, infections, unsafe abortions, and obstructed labour. 25% of these are caused by haemorrhages and are preventable, one of the measures is active management of third stage of labour (AMTSL). For prevention, treatment of postpartum haemorrhage oxytocics are available oxytocin, methylergometrine, misoprostol, prostaglandin F2α.

Methods: Study was conducted, 160 patients were randomly given one of following oxytocics a) tablet misoprostol 600 µg per rectal b) Inj. Oxytocin 10 IU IM c) Inj. Methylergometrine 0.2 mg IM d) Inj. PGF2α. Duration for the delivery of placenta and amount of blood loss was measured, side effects were noted, and comparison of haemoglobin and blood loss done.

Results: No significant difference in mean blood loss in all group with respect to parity and type of labour. In present study it seems that no oxytocic is superior to other in reducing the blood loss. Misoprostol has variable onset of action. Mean duration of 3rd stage in various groups is same. In respect to side effects HTN is common with methylergometrine, shivering and fever with misoprostol and diarrhoea with PGF2α.

Conclusions: Study concluded that all uterotonics have some advantages, oxytocin is ultimate drug of choice in skilled hand due to its definite onset of action while Tab misoprostol in unskilled hands, other oxytocin are reserved for complementary usage and treatment of PPH but Misoprostol has variable onset of action.


Keywords


Active management of 3rd stage of labor, Oxytocics, Postpartum hemorrhage

Full Text:

PDF

References


WHO: Health topics-maternal health, WHO, 2011 Available at: http://www.who.int/topics/maternal health/en/.

Abalos E. Active management of third stage of labour. RHL Commentary. The WHO Reproductive Health library, Geneva: World Health Organization 2007.

Rao SB, Fonseca M, Ajmera S, Dhanajayan B, Badhwar VR. Is oral Misoprostol a promising alternative to standard oxytocic in the third stage of labor. Available at: http://www.bhj.org/journal /2008-4401-Jan/org-30htm. Accessed on 8/14/2008.

Sultana N, Khatun M. Misoprostol versus oxytocin in the active management of third stage of labor. J Bangladesh Coll Phys Surg. 2007;25:73-6.

Parson SM, Walley RL, Crane JMG, Mathews K, Hutchens D. Rectal Misoprostol versus oxytocin in the management of the third stage of labor. J Obstet Gynaecol Can. 2009;29(9);711-8.

Vaid A, Dadhwal V, Mittal S, Deka D, Misra R, Sharma JB, et al. A randomized controlled trial of prophylactic sublingual misoprostol versus intramuscular methylergometrine versus intramuscular 15-methyl PGF2α in active management of third labour. Arch Gynecol Obstet. 2009;280:893-7.

Kumar S. A comparative study of ergometrine with oxytocin in controlling third stage blood loss-a randomized control trial. Sch J App Med Sci. 2013;1(5):595-9.

Sharma M, Kaur P, Kaur K, Kaur A, Kaur PK, Kaur MM. A comparative study of oxytocin/ misoprostol/ methylergometrine for active management of the third stage of labor. J Obstet Gynecol India. 2014;64(3):175-9.

Alam A, Shyam P, Goswami S. A comparative study of efficacy of oxytocin, methylergometrine and misoprostol in prevention of post-partum haemorrhage. Int J Reprod Contracept Obstet Gynecol. 2017;6(5):1960-4.

Afolabi EO, Kuti O, Orji EO, Ogunniyi SO. Oral misoprostol versus intramuscular oxytocin in the active management of third stage of labor. Singapore Med J. 2010;51(3):207-11.